Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Expert Opin Biol Ther. 2016 Dec 25;17(2):245–254. doi: 10.1080/14712598.2017.1271873
Drug name Tanezumab
Phase III
Indication Musculoskeletal pain and osteoarthritis
Pharmacology description Nerve growth factor antagonist/monoclonal antibody
Route of administration Injectable
Pivotal trial(s) [35,43]

Pharmaprojects - copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Informa-Pipeline (http://informa-pipeline.citeline.com) and Citeline (http://informa.citeline.com).